Materialise heads into its third-quarter report with something it has lacked for much of the past year: a credible story of profitable growth. Last quarter the Belgian 3D printing specialist raised its full-year adjusted EBIT outlook for the first time in four calls, posted its fastest revenue growth in that stretch and pulled its long-struggling manufacturing unit back into expansion. The October 28 release, due before the open, is the first real test of whether that turn was a durable shift or a single strong quarter flattered by a few hot end markets.

There is no reliable published consensus to anchor this report, so the clearest yardstick is the company's own guidance and its recent run rate. Management now targets full-year adjusted EBIT of EUR12 million to EUR14 million, up from EUR10 million to EUR12 million, while holding revenue guidance at EUR273 million to EUR283 million. Raising profit guidance without raising sales guidance says the improvement is coming from mix and cost discipline rather than a demand surge, which makes margin the number to scrutinize. Adjusted EBIT margin climbed to 5.5% last quarter from 3.7% in the first quarter. Holding near that level would support the raised range; slipping back toward the low single digits would suggest the guidance lift relied on a second-quarter peak. The year-ago comparison is also forgiving: third-quarter revenue last year was about $77.8 million, down 3.5%, with earnings of just $0.04 per share, against $79.8 million and $0.07 last quarter. Note, though, that the RapidFit and eyewear businesses have now been sold, so reported growth may look a touch softer than the underlying trend.

The operating story hinges on two engines and one drag. Medical reaccelerated to 12% growth, led by a 19% jump in devices and services, and needs to keep compounding even as the segment absorbs the departure of its leader in September. Manufacturing swung from an 8% decline to 7% growth, powered by a 40% surge in aerospace and a narrowing EBITDA loss. Evidence that the Lufthansa Technik relationship and defense work, including the Belgian Strike IT consortium, are broadening that recovery would validate the turnaround; another quarter of weak prototyping demand pulling the segment back toward losses would undercut it. Software is the drag. Revenue fell 3% after a 1% dip, segment EBITDA margin compressed to about 10% from 15.5% two quarters earlier, and deferred revenue declined, which management called seasonal. Early traction for CoAM Pro, launched a month ahead of schedule, and any sign that sales cycles are shortening would be the most encouraging signal; a third straight quarter of decline would raise questions about pricing power and the academic and orthopedic headwinds.

The stock has rewarded the improved narrative, gaining about 12.6% since the last report while the S&P 500 was roughly flat. At $8.11 it sits well above its 200-day moving average near $6.28, and its post-earnings range of $6.91 to $8.82 has shifted decisively above the prior quarter's $5.26 to $7.50 band. It is not pressing its recent high, however, and sentiment has cooled noticeably, moving to a moderately bearish reading from roughly neutral before the last report. That combination suggests a market that has priced in some of the recovery but remains skeptical it will stick.

The central question is whether margin expansion can persist while software keeps shrinking. If medical and manufacturing keep carrying the load, free cash flow stays strong and management reaffirms or nudges up its EBIT range, the inflection thesis remains intact. If software deteriorates further and margins retreat, the raised guidance will start to look ambitious, and the stock's recent premium will be harder to defend.